Brief Title: Enfortumab Vedotin (ASG-22CE) as Monotherapy or in Combination With Other Anticancer Therapies for the Treatment of Urothelial Cancer

PRIMARY OUTCOMES

Primary Outcome 1 - Measure: Type

Primary Outcome 1 - Timeframe: Through 1 month following last dose

Primary Outcome 2 - Measure: incidence

Primary Outcome 2 - Timeframe: or end-of-treatment visit whichever is later

Primary Outcome 3 - Measure: severity

Primary Outcome 3 - Timeframe: approximately 3 years anticipated.

Primary Outcome 4 - Measure: seriousness

Primary Outcome 4 - Timeframe: Through 1 month following last dose

Primary Outcome 5 - Measure: and relatedness of adverse events (Dose escalation and Expansion Parts 1 to 3 cohorts only)

Primary Outcome 5 - Timeframe: or end-of-treatment visit whichever is later

Primary Outcome 6 - Measure: Type

Primary Outcome 6 - Timeframe: approximately 3 years anticipated.

Primary Outcome 7 - Measure: incidence

Primary Outcome 7 - Timeframe: Up to 3 years

Primary Outcome 8 - Measure: and severity of laboratory abnormalities (Dose escalation and Expansion Parts 1 to 3 cohorts only)

Primary Outcome 8 - Timeframe: Up to approximately 5 months

Primary Outcome 9 - Measure: Confirmed objective response rate (ORR) per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) by blinded independent central review (BICR) (Cohort K only)

Primary Outcome 9 - Timeframe: N/A

Primary Outcome 10 - Measure: Pathological complete response (pCR) rate per central pathology review (MIBC cohorts only)

Primary Outcome 10 - Timeframe: N/A

CONDITION

• Carcinoma
• Transitional Cell
• Urinary Bladder Neoplasms
• Urologic Neoplasms
• Renal Pelvis Neoplasms
• Urothelial Cancer
• Ureteral Neoplasms
• Urethral Neoplasms

ELIGIBILITY

Inclusion Criteria:
* Locally advanced or metastatic urothelial cancer (la/mUC) - Cohorts A, B, D, E, F, G and K.
* Histologically documented la/mUC, including squamous differentiation or mixed cell types.

- * An Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0, 1 or 2: Participants with ECOG performance status of 2 must meet the following additional criteria: hemoglobin ≥10 g/dL, GFR ≥50 mL/min, may not have NYHA Class III heart failure.

- * Eligible for pembrolizumab (Dose-escalation cohorts, Cohorts A, B, G and K Combination Arm).

- * Dose-escalation cohorts: Ineligible for first-line cisplatin-based chemotherapy and no prior treatment for la/mUC, or have disease progression following at least 1 platinum-containing treatment.

- * Cohort A: Ineligible for cisplatin-based chemotherapy and no prior treatment for la/mUC. No prior adjuvant/neoadjuvant platinum-based therapy in at least 12 months.

- * Cohort B: Must have disease progression during/following treatment with at least 1 platinum-containing regimen for la/mUC or disease recurrence.

- * Cohort D: Eligible for cisplatin-based chemotherapy and no prior treatment for la/mUC. No prior adjuvant/neoadjuvant platinum-based therapy in at least 12 months.

- * Cohort E: Ineligible for cisplatin-based chemotherapy, eligible for carboplatin, and no prior treatment for la/mUC. No prior adjuvant/neoadjuvant platinum-based therapy in at least 12 months.

- * Cohort F: Ineligible for platinum-based chemotherapy, or disease progression during/following at least 1 prior treatment for la/mUC. Eligible for gemcitabine.

- * Cohort G: Eligible for platinum-based chemotherapy (either cisplatin or carboplatin) and no prior treatment for la/mUC. No prior adjuvant/neoadjuvant platinum-based therapy in at least 12 months.

- * Cohort K: Ineligible for cisplatin-based chemotherapy due to at least 1 of the following: Glomerular filtration rate (GFR) <60 mL/min and ≥30 mL/min, ECOG performance status of 2, NCI CTCAE Version 4.03 Grade ≥2 hearing loss, New York Heart Association (NYHA) Class III heart failure. No prior systemic treatment for locally advanced or metastatic disease. No adjuvant/neoadjuvant platinum-based therapy within 12 months prior to randomization. - * Muscle Invasive Bladder Cancer (MIBC)- Cohorts H, J and L.
* Histologically confirmed MIBC with predominant >50% urothelial histology: Cohorts H and J: Clinical stage cT2-T4aN0M0; Cohort L: Clinical stage cT2-T4aN0M0 or cT1-T4aN1M0: Participants with pT1 disease are eligible only if they have N1 disease on imaging. Mixed cell types are eligible if urothelial cancer is predominant (>50%); Participants with plasmacytoid and/or neuroendocrine tumors are ineligible regardless of component percentage. Urothelial tumors not originating in the bladder (eg, upper tract tumors, urethral tumors) are ineligible.

- * Must be cisplatin-ineligible.

- * Cohort-specific eligibility: Cohort J, H, and L: No prior systemic treatment, chemoradiation, or radiation therapy for MIBC. May have received prior intravesical Bacillus Calmette-Guerin (BCG) or intravesical chemotherapy for non-MIBC; Cohort J: Eligible for pembrolizumab.

- * ECOG performance status of 0, 1, or 2.

- * Anticipated life expectancy of ≥3 months.

- * Tumor samples with an associated pathology report from the diagnostic transurethral resection of a bladder tumor done 90 days prior to the first dose of study treatment must be available prior to enrollment and determined to be sufficient for pathology review and biomarker analysis.

- * Participants must be deemed eligible for RC+PLND.
Exclusion Criteria:
* la/mUC - Cohorts A, B, D, E, F, G, and K
* Received any prior treatment with a PD-1 inhibitor, PD-L1 inhibitor, or PD-L2 inhibitor, except Cohort F.

- * Received any prior treatment with stimulatory or co-inhibitory T-cell receptor agents, such as CD137 agonists, OX-40 agonists, or cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) inhibitors (except Cohort F).

- * Ongoing sensory or motor neuropathy Grade 2 or higher.

- * Active central nervous system (CNS) metastases.

- * Ongoing clinically significant toxicity (Grade 2 or greater) associated with prior treatment (including radiotherapy or surgery).

- * Conditions requiring high doses of steroids or other immunosuppressive medications.

- * Prior treatment with enfortumab vedotin or other monomethyl auristatin E (MMAE)-based antibody-drug conjugates (ADCs).

- * Uncontrolled diabetes mellitus.

- * MIBC - Cohorts H, J, and L
* Received prior systemic treatment, chemoradiation, and/or radiation therapy of muscle invasive bladder cancer.

- * Received any prior treatment with a CPI.

- * Received any prior treatment with stimulatory or co-inhibitory T-cell receptor agents, such as CD137 agonists, CTLA-4 inhibitors, or OX-40 agonists.

- * For participants in Cohort H, evidence of nodal disease on imaging. For participants in Cohort L, ≥N2 nodal disease on imaging.

- * Participant has undergone partial cystectomy of the bladder to remove any NMIBC or MIBC.

- * Ongoing sensory or motor neuropathy Grade 2 or higher.

- * Conditions requiring high doses of steroids or other immunosuppressive medications.

- * Prior treatment with enfortumab vedotin or other MMAE-based ADCs for urothelial cancer.

- * Participants with a history of another invasive malignancy within 3 years before first dose of study drug.

Gender: All

Minimum Age: 18 Years

Maximum Age: N/A

Healthy Volunteers: No

OFFICIAL INFORMATION

Name: Changting Meng, MD, Jason Lukas, MD, PhD

Role: Study Director, Study Director

Affiliation: Seagen Inc., Seagen Inc.

Overall Contact

Name: N/A

Phone: N/A

Email: N/A

LOCATION